**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Stefano H Byer, MD; University of Iowa Hospitals and Clinics, Iowa City, IA

**Main Body of the Abstract**
Improved diagnostics and clinician awareness have resulted in increased incidence and prevalence of cardiac amyloidosis. Most patients refer to online patient information to develop and expand their understanding of this complex disease. Our study assesses if readability produced by academic medical centers (AMCs) is inclusive of the NIH standard of a reading level 8 or below.
We identified a total of 32 AMC websites providing cardiac amyloidosis patient information reviewing pathophysiology and treatment. Text from the websites were extracted and subjected to 10 validated readability assessment tools. Using JMP 15 (SAS Institute, Cary, North Caroling, USA) we performed simple linear regression between median readability and possible independent variables: word count, U.S. News ranking, and Google Search ranking metrics.
Overall median reading level was 11.3 (IQR 10.5 –11.9), thus the 32 AMC websites identified failed to provide inclusive educational material. No correlation between word count and readability was identified (r2 = 0.00, p=0.95). The relationship between google search ranking or US News ranking suggests perceived AMC status did not correlate with ability to connect with the general population (r2 = 0.021, p=0.42 and r2 = 0.013, p=0.65, respectively).
There is a paucity of patient education information focusing on cardiac amyloidosis inclusive of the general population reading level. Providing educational material in this growing disease class that meets the NIH readability standards is critical to address patient needs.



A readability analysis of online patient information for cardiac amyloidosis  PB94 (#256)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.